| CNS Pharmaceuticals is a clinical pharmaceutical company. Co. focuses on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. Co.'s primary focus is on the development and testing of Berubicin, a development stage anthracycline intended to treat glioblastoma. Berubicin intercalates into deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. We show 20 historical shares outstanding datapoints in our coverage of CNSP's shares outstanding history.
Understanding the changing numbers of CNSP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CNSP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CNSP by allowing them to research CNSP shares outstanding history
as well as any other stock in our coverage universe.